- Home
- CIFR vs LEGN Comparison
CIFR vs LEGN Comparison
Compare CIFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | LEGN |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIFR | LEGN |
|---|---|---|
| Price | $14.85 | $18.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $24.45 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 26.5M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.59 | $67.56 |
| Revenue Next Year | $192.90 | $43.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.86 | $16.24 |
| 52 Week High | $25.52 | $45.30 |
Technical Indicators
Market Signals| Indicator | CIFR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 41.00 |
| Support Level | $13.84 | $16.24 |
| Resistance Level | $15.54 | $23.68 |
| Average True Range (ATR) | 1.48 | 0.88 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 19.33 | 8.09 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.